Axel Leimer

Axel H. Leimer (born 1963) is the chief business officer at Vectron.

Leimer was born in Frankfurt, Germany and has studied biochemistry at the University of Colorado and Baylor College of Medicine. He worked on dual action protease inhibitors and is co-inventor of a series of serine and cysteine inhibitors. He described several interleukin-converting enzyme ("ICE") inhibitors and coauthored a study on alternative . His work also includes combining pharmacophores of Bradykinin B1 and B2 anatagonists with that of a protease inhibitor for the treatment of inflammatory diseases. His work also included the identification of a small molecular weight glycosylated serum ferritin secreted from the heart, showing that the heart acts as an endocrine organ.

Leimer has been managing director of Source Precision Medicine Europe and Executive Board Member and CBO/COO of Vectron Pharmaceuticals AG, Marburg, Germany. He is currently managing a consulting business and is Investment Advisor of Future Capital AG. Previous employment includes Hoechst AG, Frankfurt, Germany, Rocky Mountain BankCard, Cortech Inc., Denver, Colorado and Vertex Pharmaceuticals, Cambridge, Massachusetts. Leimer has continued to serve as an advisor to various chemical studies.

Leimer is co-founder of Kinaxo GmbH, Munich. He has continued to be involved in this groups endevors.

Leimer has served from 2001 through 2007 as a bishop in The Church of Jesus Christ of Latter-day Saints in Frankfurt-Höchst, Germany and was called as president of an LDS Church stake in June 2007.

Main Menu

See Also

Main Menu